4D Molecular Therapeutics granted 96,000 Restricted Stock Units to seven new non-executive employees on September 8, 2026. The awards were approved by the compensation committee of the company’s board of directors under its 2025 Employment Inducement Award Plan, as amended, pursuant to Rule 5635(c)(4) of The Nasdaq Global Market. 4DMT is developing 4D-150 for wet age-related macular degeneration and diabetic macular edema, along with 4D-710 for cystic fibrosis; all product candidates remain unapproved and are in clinical or preclinical development.